
#55. AI for Drug Patents
Episode 12
In this episode, we explore the evolving landscape of AI-driven pharmaceutical intellectual property, emphasizing that, for patent offices, artificial intelligence is viewed as a computational tool rather than an inventor. Effective legal strategies require a layered portfolio that protects not only the AI platform but also the specific therapeutic molecules, medical uses, and biomarkers discovered through these workflows. Success stories like Insilico Medicine’s rentosertib demonstrate that high-value patents must move beyond in silico predictions to include experimental validation, such as synthesis procedures and animal model data. Developers are cautioned to maintain rigorous human inventorship records to ensure that individuals, not algorithms, are credited with the creative conception of new drugs. Furthermore, the documents highlight a strategic tension between patenting repeatable workflows and maintaining proprietary training data or model weights as trade secrets. Ultimately, a robust defense against competitors relies on combining traditional drug patent substance with clear evidence of the technical improvements enabled by AI integration. Produced by Dr. Jake Chen.
Publisher
Drug Discovery AI Talk
Link
podcasters.spotify.com/pod/show/jakechen/episodes/55--AI-for-Drug-Patents-e3ip4pg
Published
May 2, 2026
Duration
21 min
Format
Podcast
Category
Issues · Tech News
Source
RSS feed
Host
Dr. Jake Chen
Drug Discovery AI Talk
@drugdiscoveryaitalk
#drugpatents
